T1	p 191 238	herpes zoster ( HZ ) and postherpetic neuralgia
T2	p 262 297	individuals > or =60 years of age .
T3	p 473 548	in subjects > or =50 years of age . Subjects with a negative history for HZ
T4	p 628 672	stratified 1:2 by age ( 50 to 59 years and >
T5	i 98 164	refrigerator-stable formulation of Zostavax . The vaccine Zostavax
T6	i 357 388	refrigerator-stable formulation
T7	i 400 414	refrigerated )
T8	i 441 452	formulation
T9	i 455 472	Zostavax frozen )
T10	i 599 612	formulation .
T11	o 690 696	Safety
T12	o 741 790	Varicella-zoster virus ( VZV ) antibody responses
T13	o 902 943	VZV antibody geometric mean titer ( GMT ;
T14	o 959 997	VZV antibody geometric mean rise ( GMR
T15	o 1025 1089	incidence of vaccine-related serious adverse experiences ( AEs )
T16	o 1186 1190	GMTs
T17	o 1249 1316	estimated GMT ratio ( refrigerated formulation/frozen formulation )
T18	o 1424 1451	vaccine-related serious AEs
T19	o 1492 1507	safety profiles
T20	o 1557 1590	frequencies of injection-site AEs
T21	o 1732 1759	frequencies of systemic AEs
T22	o 1932 1938	safety
T23	o 1957 1968	immunogenic